

Appendix from Gall et al., “An international physician survey of chronic thromboembolic pulmonary hypertension management” (Pulm. Circ., vol. 6, no. 4, p. 472)


Table S1. Physician sample, continued

	UK	FR	DE	IT	ES	US	AR	JP
No. of physicians	50	52	51	50	57	152	52	32
Patients with CTEPH currently managed, %								
2–10	52	55.8	33.3	62	56.1	36.8	98.1	81.2
11–20	12	17.3	25.5	18	24.6	18.4	0	3.1
21–30	14	3.8	23.5	4	3.5	10.5	0	0
31 or more	22	23.1	17.6	16	15.8	34.2	1.9	0
Patients with CTEPH currently managed, no.								
Mean ± SEM	27.6 ± 5.9	37.8 ± 11.2	25.9 ± 4.7	21.4 ± 4.9	17 ± 2.5	38.4 ± 5.1	6.3 ± 2.8	4.5 ± 0.7
Median	10	10	18	10	10	20	3	3

Note: AR: Argentina; CTEPH: chronic thromboembolic pulmonary hypertension; DE: Germany; ES: Spain; FR: France; IT: Italy; JP: Japan; SEM: standard error of the mean; UK: United Kingdom; US: United States.

A) Europe: PH Center

Clinical evaluation for PEA in patients with CTEPH receiving PAH-specific drug therapy: patient records (PH center)



B) Europe: non-PH center

Clinical evaluation for PEA in patients with CTEPH receiving PAH-specific drug therapy: patient records (non-PH center)





Figure S1. Clinical evaluation for PEA in patients with CTEPH receiving PAH-specific drug therapy in PH centers and non-PH centers (patient record data for patients diagnosed with CTEPH and currently receiving PAH-specific drug therapy). BPA: balloon pulmonary angioplasty; CTEPH: chronic thromboembolic pulmonary hypertension; mPAP: mean pulmonary artery pressure; NYHA: New York Heart Association; PAH: pulmonary arterial hypertension; PEA: pulmonary endarterectomy; PH: pulmonary hypertension; pt: patient; PVR: pulmonary vascular resistance.

C) United States: PH center

Clinical evaluation for PEA in patients with CTEPH receiving PAH-specific drug therapy: patient records (PH center)



D) United States: non-PH center

Clinical evaluation for PEA in patients with CTEPH receiving PAH-specific drug therapy: patient records (non-PH center)





Figure S1 (Continued)

E) Argentina: PH center
Clinical evaluation for PEA in patients with CTEPH receiving PAH-specific drug therapy: patient records (PH center)



F) Argentina: non-PH centers
Clinical evaluation for PEA in patients with CTEPH receiving PAH-specific drug therapy: patient records (non-PH center)




Figure S1 (Continued)




Figure S1 (Continued)







Figure S2. Clinical evaluation for PEA and PAH-specific drug therapy in patients with CTEPH (physician perception data). Numbers are the mean number of patients per physician (percentage of patients as a proportion of each subgroup). BPA: balloon pulmonary angioplasty; CTEPH: chronic thromboembolic pulmonary hypertension; PAH: pulmonary arterial hypertension; PEA: pulmonary endarterectomy; PH: pulmonary hypertension.



* Clinical evaluation at an institution with a department specialized in PH treatment.



* Clinical evaluation at an institution with a department specialized in PH treatment.

Figure S2 (Continued)